KLK3 and cancer: Additionally, GPS predicted high-grade and/or high-stage disease, after controlling for established clinical factors (age, PSA, clinical stage, biopsy GS), resulting in an OR of 2.1 (95% CI, 1.4–3.2) when adjusting for the Cancer of the Prostate Risk Assessment score (CAPRA).